Remove astrazeneca-sanofi-tee-3-way-rsv-battle-2023-fda-signals-expedited-review-antibody
article thumbnail

AstraZeneca, Sanofi tee up 3-way RSV battle in 2023 as FDA signals expedited review for antibody

Fierce Pharma

AstraZeneca, Sanofi tee up 3-way RSV battle in 2023 as FDA signals expedited review for antibody. Thu, 01/05/2023 - 10:13.

FDA 213